Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Business, basis of presentation, new accounting standards and summary of significant accounting policies
Common stock, shares authorized	100,000	100,000
Cash	$ 16,017	$ 22,435
Accumulated deficit	135,857	108,265
Net loss	(27,592)	(12,470)
Net cash used in operating activities	24,710	10,799
Clinical trial accrued liabilities	1,696	3,033
Accrued expenses and other current liabilities	785	$ 592
Common stock for no additional consideration	$ 1
Minimum
Business, basis of presentation, new accounting standards and summary of significant accounting policies
Estimated useful life	3 years
Maximum
Business, basis of presentation, new accounting standards and summary of significant accounting policies
Estimated useful life	5 years
Revision of Prior Period, Reclassification, Adjustment [Member]
Business, basis of presentation, new accounting standards and summary of significant accounting policies
Clinical trial accrued liabilities	$ 3,000
Accrued expenses and other current liabilities	$ 800